Inhibition of osteocyte apoptosis prevents the increase in osteocytic receptor activator of nuclear factor κB ligand (RANKL) but does not stop bone resorption or the loss of bone induced by unloading by Plotkin, Lilian I. et al.
Inhibition of Osteocyte Apoptosis Prevents the Increase in
Osteocytic Receptor Activator of Nuclear Factor B Ligand
(RANKL) but Does Not Stop Bone Resorption or the Loss of
Bone Induced by Unloading*
Received for publication, January 29, 2015, and in revised form, June 16, 2015 Published, JBC Papers in Press, June 17, 2015, DOI 10.1074/jbc.M115.642090
Lilian I. Plotkin‡§1, Arancha R. Gortazar‡2, HannahM. Davis‡, Keith W. Condon‡, Hugo Gabilondo‡3, Marta Maycas‡4,
Matthew R. Allen‡, and Teresita Bellido‡§¶5
From theDepartments of ‡AnatomyandCell Biologyand ¶Medicine,Divisionof Endocrinology, IndianaUniversity School ofMedicine,
Indianapolis, Indiana46202and the §RoudebushVeteransAdministrationMedical Center, Indianapolis, Indiana46202
Background: Osteocyte apoptosis precedes bone loss induced by reduced mechanical forces, and unloading increases
RANKL expression.
Results: Inhibition of osteocyte apoptosis prevents increased osteocytic RANKL but not bone loss induced by tail suspension.
Conclusion:Prevention of apoptosis and reduction of osteocytic RANKLare not sufficient to stop unloading-induced bone loss.
Significance: RANKL from non-osteocytic sources contributes to bone loss induced by reduced mechanical forces.
Apoptosis of osteocytes and osteoblasts precedes bone
resorption and bone loss with reduced mechanical stimulation,
and receptor activator of NF-B ligand (RANKL) expression is
increased with unloading in mice. Because osteocytes are major
RANKL producers, we hypothesized that apoptotic osteocytes
signal to neighboring osteocytes to increase RANKL expression,
which, in turn, increases osteoclastogenesis and bone resorp-
tion. The traditional bisphosphonate (BP) alendronate (Aln) or
IG9402, a BP analog that does not inhibit resorption, prevented
the increase in osteocyte apoptosis and osteocytic RANKL
expression. The BPs also inhibited osteoblast apoptosis but did
not prevent the increase in osteoblastic RANKL. Unloadedmice
exhibited high serum levels of the bone resorptionmarker C-te-
lopeptide fragments of type I collagen (CTX), elevated oste-
oclastogenesis, and increased osteoclasts in bone. Aln, but not
IG9402, prevented all of these effects. In addition, Aln pre-
vented the reduction in spinal and femoral bone mineral den-
sity, spinal bone volume/tissue volume, trabecular thickness,
mechanical strength, and material strength induced by unload-
ing. Although IG9402 did not prevent the loss of bone mass, it
partially prevented the loss of strength, suggesting a contribu-
tion of osteocyte viability to strength independent of bonemass.
These results demonstrate that osteocyte apoptosis leads to
increased osteocytic RANKL.However, blockade of these events
is not sufficient to restrain osteoclast formation, inhibit resorp-
tion, or stop bone loss induced by skeletal unloading.
Mechanical forces have a positive effect on the skeleton and,
in contrast, conditions underwhich decreased strain is imposed
on bone lead to loss of bone mass and an increased risk of
fractures (1). Such conditions include prolonged bed rest, phys-
ical inactivity, motor paralysis because of denervation, and
reduced gravity. With the rise in the aging population, the pre-
dominance of a sedentary life style, and the prospective of com-
mercialization of space flights, there is an increased need for
understanding the mechanisms underlying the loss of bone
with skeletal unloading and for new approaches to combat it.
Osteocytes are recognized mechanosensory cells of bone
that detect the need for bone augmentation or reduction in
response to changes in mechanical stimulation (2). Recent
advances in osteocyte biology demonstrate that osteocytes pro-
ducemolecules that regulate the generation and activity of both
osteoblasts and osteoclasts (3). The protein sclerostin encoded
by the gene Sost is secreted by osteocytes and inhibits bone
formation by osteoblasts, providing the first example of a
molecular mediator produced by matrix-embedded osteocytes
that regulate the activity of cells on the bone surface (4). Sost/
sclerostin expression is down-regulated by mechanical stimu-
lation, an event that is required for the anabolic response of the
skeleton to loading (5, 6). Further, sclerostin expression is
increased with unloading, potentially explaining the decreased
bone formation that ensueswith disuse osteoporosis (6).Osteo-
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cytes also produce pro- and anti-osteoclastogenic cytokines
that regulate bone resorption, including osteoprotegerin
(OPG)6 and receptor activator of NF-B ligand (RANKL)
(7–11). In particular, mice lacking the RANKL gene primarily
from osteocytes exhibit a progressive increase in bone mass
because of a reduced number of osteoclasts, demonstrating that
osteocytic RANKL is critical for bone remodeling (10, 11).
However, the mechanisms that regulate RANKL and OPG
expression in osteocytes in response to mechanical forces (or
lack thereof) are not known.
Earlier work demonstrated that physiological levels of load-
ingmaintain osteocyte viability in vitro and in vivo (12–15). On
the other hand, unloaded bone or bone subjected to excessive
loading exhibit an increased prevalence of osteocyte apoptosis
(14, 16). Furthermore, apoptosis of osteocytes precedes tempo-
rally and spatially osteoclast-mediated resorption because apo-
ptotic osteocytes are found in bone before any detectable
increase in osteoclasts and accumulate in areas that will be sub-
sequently resorbed (14, 16). Moreover, the targeted ablation of
osteocytes by genetic means is sufficient to increase RANKL
and to induce osteoclast recruitment and bone resorption (17).
However, whether the increase in osteocyte apoptosis and
RANKL expression induced by unloading are mechanistically
linked remains unknown. In addition, whether preserving
osteocyte viability alters RANKL expression, osteoclast gener-
ation, and/or bone resorption in unloaded bones has not been
explored before.
In this study, we addressed these questions using two bispho-
sphonate (BP) analogs that, as we showed previously, effectively
block osteocyte and osteoblast apoptosis in vitro and apoptosis
induced by glucocorticoid excess in vivo (18–21). The mecha-
nism by which these agents prevent apoptosis of osteoblastic
cells involves opening of connexin 43 hemichannels and activa-
tion of the prosurvival Src/ERK signaling pathway (21, 22). Tra-
ditional BPs such as alendronate also inhibit the mevalonate
pathway and intoxicate osteoclasts, thereby inhibiting resorp-
tion (23). In contrast, the unique BP analog IG9402 only acts on
osteocytes and osteoblasts and does not inhibit the mevalonate
pathway or bone resorption (19, 21, 24). Furthermore, daily
injections with alendronate decreases bone formation as a con-
sequence of its antiresorptive activity (21). This was evidenced
by reduced plasma levels of CTX and osteocalcin and mineral-
izing surface/bone surface (MS/BS), mineral apposition rate
(MAR), and bone formation rate/bone surface (BFR/BS) and
osteoblast number in cancellous bone. On the other hand,
IG9402 did not affect any of these parameters in vehicle-treated
mice.Moreover, IG9402 prevented the decrease in bone forma-
tion and osteoblast number in glucocorticoid-treated mice.
Using these two pharmacologic tools, we dissected the contri-
bution of osteocyte and osteoblast apoptosis to the changes in
RANKL and OPG expression and to the increased resorption
triggered by skeletal unloading.
We found that both BPs inhibited osteocyte and osteoblast
apoptosis and decreased RANKL expression in osteocytes. In
contrast, even when osteoblast apoptosis induced by unloading
was inhibited by the bisphosphonates, the increased RANKL
expression in osteoblasts was not reversed by the drugs. Alen-
dronate also prevented the elevation in osteoclasts, bone
resorption, and bone loss induced by unloading. In contrast,
IG9402 did not prevent the increase in osteoclasts or bone
resorption or the decrease in bone mass. These findings show
that osteocyte apoptosis does indeed control osteocytic
RANKL expression and that maintaining osteocyte viability is
not sufficient to restrain resorption or prevent the loss of bone
induced by unloading. Therefore, RANKL derived from non-
osteocytic sources (likely osteoblasts)mediates osteoclastogen-
esis and the bone loss resulting from lack of mechanical forces.
Experimental Procedures
Tail Suspension—Female 4-month-old C57BL/6 mice (Har-
lan) were used. Mice were kept in cages under standard labora-
tory conditions with a 12-h dark, 12-h light cycle, a constant
temperature of 20 °C, and a humidity of 48% for 2 weeks for
acclimation. Mice were fed a standard rodent diet (Purina For-
mulaLab Diet 5008) with water ad libitum. Skeletal unloading
was achieved using the tail suspension model described previ-
ously (14). The height was adjusted to maintain the mice in an
30° head-down tilt. Two tail-suspended animals were housed
per cage. Fully ambulatory controlmicewere caged in groups of
five and pair-fed with the tail-suspended mice. All protocols
were approved by the Indiana University School of Medicine.
Bone Resorption Marker—CTX were measured using an
enzyme-linked immunoadsorbent assay (RatLaps, Immunodi-
agnostic Systems Inc., Fountain Hills, AZ), as published previ-
ously (21).
Ex Vivo Osteoclastogenesis—Bone marrow cells collected
from tibiae and femora of six mice of each group were com-
bined and seeded in triplicates at a density of 50  103 cells/
cm2. Cells were cultured in the presence of 30 ng/ml macro-
phage colony-stimulating factor (M-CSF) and 30 ng/ml soluble
RANKL for 4 days. Cells when then fixed and stained for tar-
trate-resistant acid phosphatase (TRAP) as published previ-
ously (19).
TUNEL, Immunohistochemistry, and TRAP Staining—Ver-
tebrae (L3-L4) were decalcified and paraffin-embedded as
described previously (25). Consecutive 5-m-thick sections
were used for osteocyte apoptosis and for analysis of protein
expression by immunohistochemistry. For apoptosis, a modi-
fied version of a commercial TUNEL kit (EMD Millipore, Bil-
lerica,MA)was used, and sectionswere counterstainedwith 2%
methyl green, as described previously (20). Immunohistochem-
istry was performed in consecutive sections using goat anti-
RANKL and anti-OPG antibodies (Santa Cruz Biotechnology
Inc., Santa Cruz, CA) with prior antigen retrieval (DeCal
Retrieval Solution, BioGenex, San Ramon, CA) and followed by
signal amplification (ABC kit, Vector Laboratories, Burlin-
game, CA). Non-immune IgG was used as a negative control.
Cells were score as either positive (brown staining) or negative
(blue/green staining) for each antigen. To visualize osteoclasts
on the cancellous bone surface, sections were stained for TRAP
6 The abbreviations used are: OPG, osteoprotegerin; RANKL, receptor activa-
tor of NF-B ligand; BP, bisphosphonate; CTX, C-telopeptide fragments of
type I collagen; BMD, bone mineral density; microCT, microcomputed
tomography; BV/TV, bone volume/tissue volume; ANOVA, analysis of
variance.
Osteocyte Apoptosis and Osteocytic RANKLwith Unloading
JULY 31, 2015•VOLUME 290•NUMBER 31 JOURNAL OF BIOLOGICAL CHEMISTRY 18935
and counterstained with toluidine blue, as described previously
(25).OnlyTRAP-positive cells containingmore than twonuclei
were counted.
MLO-Y4 Osteocytic and Ob-6 Osteoblastic Cell Culture—
Cells were cultured as published previously (18, 26). For gene
analysis and trypan blue uptake, cells were treated with vehicle
or 107 M alendronate or IG9402 for 1 h, followed by addition of
vehicle, dexamethasone (106 M), etoposide (20 M), or H2O2
(100 M) in growing medium or with medium without serum
for the indicated time points. Cells were then trypsinized to
determine the percentage of dead cells by trypan blue uptake or
lysed to isolate mRNA, as published previously (26). For the
experiments using conditionedmedium, cellswere treatedwith
vehicle or bisphosphonate for 1 h, followed by addition ofH2O2
or by changing themedium to remove the serum. 6, 24, and 48 h
later, culture supernatants were collected and added to cells
plated the day before (together with growing medium, 1:1). 6
and 24 h later, cells were lysed to collect mRNA.
RNA Preparation and Real-time PCR—RNA was isolated
from MLO-Y4 cells using TRIzol reagent (Invitrogen), as
described previously (27). Quantitative PCR was performed
using the housekeeping gene ribosomal protein S2 (ChoB) and
the Ct method. Primers and probes were designed using the
Assay Design Center (Roche Applied Science) or were available
commercially (Applied Biosystems, Foster City, CA).
BoneMineral Density (BMD) andMicrocomputed Tomogra-
phy (MicroCT) Analysis—BMDof the total body (excluding the
head), spine (L1-L6), and femur was determined by dual energy
x-ray absorptiometry using a PIXImus II densitometer (GE
Medical Systems, Lunar Division, Madison, WI), as described
previously (28). For microCT analysis, L5 vertebrae were dis-
sected, cleaned of soft tissue, fixed, and stored in 70% ethanol
until analyzed at 6-m resolution using a Skyscan 1172
microCT (SkyScan, Kontich, Belgium) (28). Analyses were con-
ducted on cancellous bone to measure bone volume/tissue vol-
ume (BV/TV), trabecular number (Tb.N), spacing (Tb.Sp), and
thickness (Tb.Th); on cortical bone tomeasure the thickness of
the posterior shell (cortical thickness); and on cortical and can-
cellous combined normalized to total area (total BV/TV).
Biomechanical Testing—Compression strength was mea-
sured in lumbar vertebrae (L6) using a single-column material
testingmachine and a calibrated tension/compression load cell
(model 5542, Instron Corp., Norwood, MA) (21). Bone dimen-
sions weremeasuredwith a digital caliper at a resolution of 0.01
mm (Mitutoyo, catalog no. 500-196, Ace Tools,Wantagh, NY).
Statistical Analysis—Statistical analysis was performed using
SigmaStat (SPSS Science, Chicago, IL). Data were analyzed by
two-way ANOVA, and, if a significant main effect or interac-
tion was found, we examined it closely by performing pairwise
multiple comparisons with Bonferroni correction (29). All val-
ues are reported as the mean S.D.
Results
Increased Osteocyte and Osteoblast Apoptosis and Accumu-
lation of RANKL-positive Osteocytes Induced by Lack of
Mechanical Stimulation Is Prevented by Bisphosphonates
Independently of Their Antiresorptive Potential—Our previous
work has shown that tail suspension consistently decreases
bone mass and strength and increases osteoblast and osteocyte
apoptosis in lumbar vertebral bone of Swiss Webster and
C57BL/6 mice (14). We therefore examined the effect of BP
administration on vertebral bone of unloaded mice. Tail sus-
pension induced an increase in the prevalence of apoptotic
osteocytes and osteoblasts in cancellous bone of the lumbar
vertebra (Fig. 1). As found previously for glucocorticoid-in-
duced apoptosis (21), daily injections of alendronate or IG9402
preserved both osteoblast and osteocyte viability. The preva-
lence of RANKL-positive osteocytes was increased significantly
in vertebral bone from 7% in controls to 14% in mice sub-
jected to tail suspension (Fig. 2A). This increase was completely
prevented by daily administration of alendronate or IG9402.
Tail suspension also increased the prevalence of RANKL-posi-
tive osteoblasts from13% in controls to 23% inmice subjected
to tail suspension, but neither alendronate nor IG9402 admin-
istration prevented this effect. The prevalence of OPG-positive
osteocytes, which ranged from 19–25% in ambulatory control
mice, was decreased by tail suspension (10–12%), independent
of whether the animals received saline, alendronate, or IG9402
(Fig. 2B). On the other hand, the prevalence of OPG-positive
FIGURE 1. Alendronate and IG9402 prevent immobilization-induced
osteocyte and osteoblast apoptosis. The prevalence of osteocyte and
osteoblast apoptosis was determined in vertebral bone sections stained for
TUNEL. Error bars represent themean S.D. of five to nine replicas. *,p 0.05
versus the respective ambulatory control by two-way ANOVA. Images are
representativeof sectionswith alive (white arrows) or apoptotic (black arrows)
osteocytes and osteoblasts. Scale bars 25 m.
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osteoblasts was decreased in mice subjected to tail suspension
and receiving vehicle or IG9402 (37 and 17% OPG-positive
osteoblasts for control and tail-suspended mice, respectively),
whereas alendronate administration reversed the decrease in
OPG-expressing osteoblasts (25 and 38% OPG-positive
osteoblasts for alendronate-treated control and tail-suspended
mice, respectively). On the other hand, OPG expression in the
bone marrow was not altered by any of the treatments. Taken
together, this evidence suggests that signals from apoptotic
osteocytes increase RANKL expression in osteocytes without
modifying OPG expression and that the regulation of RANKL
andOPGexpression in osteoblasts is independent of changes in
cell survival.
To determine whether inhibition of RANKL expression by
alendronate or IG9402 is reproduced in vitro, we treated
MLO-Y4 osteocytic cells and Ob-6 osteoblastic cells with dif-
ferent proapoptotic agents (dexamethasone, etoposide, H2O2,
and serum starvation) in the presence or absence of bisphos-
phonates. Cells were cultured for 2, 6, 24, or 48 h with the
proapoptotic agents, and RNA was extracted. We found that
the proapoptotic agents induced apoptosis of osteocytic cells
and that the bisphosphonates prevented apoptosis (data not
shown), as published previously (18, 20, 22). However, RANKL
expressionwas not affected either by the proapoptotic agents or
by the bisphosphonates. In addition, and to determine whether
soluble factors derived from apoptotic cells were able to
increase RANKL expression, conditioned medium from
MLO-Y4 osteocytic cells or Ob-6 osteoblastic cells treated with
H2O2 or undergoing serum starvation was placed on a new set
of cells, and RANKL expression was measured after 6 or 24 h.
Conditioned media from none of the treatments/times
increased RANKL expression in MLO-Y4 cells or Ob-6 cells.
Taken together, these findings suggest that bisphosphonates do
not regulate RANKLexpression directly on osteocytes or osteo-
blasts and that soluble factors derived fromosteocytes or osteo-
blasts are not sufficient to increase RANKL expression in vitro.
FIGURE 2. Prevention of osteocyte apoptosis is associated with reduced prevalence of RANKL-positive osteocytes and no change in OPG-positive
osteocytes in immobilized mice. A and B, the prevalence of RANKL- (A) and OPG-positive (B) osteocytes and osteoblasts was determined in vertebral bone
sections stainedwith the respective antibodies. Error bars represent themean S.D. of three to six replicas. *,p0.05 versus the respective ambulatory control
mice; #, p 0.05 versus saline-treated tail-suspendedmice; two-way ANOVA. Images are representative of sections with osteocytes negative (white arrows) or
positive (black arrows) for the indicated protein. Scale bars 25 m. Insets correspond to sections stained with non-immune IgG.
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Osteoclastogenesis and Bone Resorption Induced by Tail Sus-
pension Are Prevented by Alendronate but Not by IG9402—The
levels of CTX in the circulation were increased in mice sub-
jected to tail suspension (Fig. 3A). Daily alendronate adminis-
tration reduced CTX levels under ambulatory conditions and
prevented the increase observed in tail-suspendedmice. On the
other hand, IG9402 did not affect circulating CTX levels in
either group of mice. Consistent with this, osteoclastogenesis
induced ex vivo using non-adherent bonemarrow cells isolated
from the treated mice was increased in tail-suspended animals,
inhibited by alendronate, and not affected by IG9402 (Fig. 2B).
Moreover, osteoclast number and surface in the vertebra fol-
lowed a similar pattern (Fig. 3C). However, there was a small
but significant decrease in the number of osteoclast/bone sur-
face in tail-suspended mice treated with IG9402 compared to
saline-treated tail-suspended animals. Alendronate adminis-
tration induced the appearance of giant osteoclasts and small,
darkly stained TRAP-positive cells that appeared to be encap-
sulated in the bone marrow (Fig. 4). These were present inde-
pendent of whether the mice were subjected to tail suspension
or not and are consistent with previous evidence of giant inac-
tive osteoclasts found in humans treated with BPs (30, 31).
IG9402 Does Not Preserve Bone Mass but Partially Prevents
the Decrease in Bone Strength Induced by Tail Suspension in
Mice—Tail suspension for 28 days induced a decrease in total,
spinal, and femoral BMD (Fig. 5). As described previously (20),
daily administration of alendronate increased BMD in all sites
in ambulatory controls and prevented bone loss induced by
unloading. On the other hand, IG9402 did not have any effect
either under ambulatory or tail-suspended conditions. Similar
changes were observed by microCT because tail suspension
decreased cancellous BV/TV and trabecular number and thick-
ness without changing trabecular spacing (Fig. 6A). Alendro-
nate increased BV/TV and trabecular number and thickness in
ambulatory controls and prevented the decrease in tail-sus-
pended mice. IG9402 did not affect the decrease in BV/TV and
trabecular thickness observed in tail-suspended mice, but the
trabecular number was not different in IG9402-treated, tail-
FIGURE 3. Alendronate, but not IG9402, inhibits osteoclastogenesis ex vivo and decreases osteoclast number and function in vivo. A, levels of the
resorption marker CTX were measured in serum at the end of the experiment. Error bars represent the mean S.D. of 11–13 replicas. *, p 0.05 versus the
respective ambulatory control; #, p  0.05 versus saline-treated, tail-suspended mice; two-way ANOVA. B, osteoclasts were generated ex vivo by treating
non-adherentbonemarrowcellswithM-CSF and sRANKL, as indicatedunder “Experimental Procedures.” Error bars represent themean S.D. of three replicas.
*, p  0.05 versus the respective ambulatory control; #, p  0.05 versus saline-treated, tail-suspended mice; two-way ANOVA. Representative images of
osteoclasts for each treatment are shown. Scale bars  100 m. C, number of osteoclasts per bone perimeter (NOc/BPm) and osteoclast surface per bone
surface (OcS/BS) were quantified in vertebral bone sections stained for TRAP. Error bars represent mean  S.D. of five to six replicas. *, p  0.05 versus the
respective ambulatory control; #, p 0.05 versus saline-treated, tail-suspendedmice; two-way ANOVA. Representative images of cancellous bone are shown.
Scale bars 50 m.
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suspended mice compared with ambulatory mice treated with
the same BP. Similar changes were observed in vertebral corti-
cal thickness (Fig. 6B) and in total BV/TV (Fig. 6C), which
includes both cancellous and cortical bone.
Immobilization induced a decrease in vertebral strength at
both the whole bone level (maximum load) and estimated
material level (ultimate stress), and alendronate prevented
these effects (Fig. 7). Therefore, there was no difference in ulti-
mate load, and the difference in ultimate stress was greatly
reduced in alendronate-treated, tail-suspendedmice compared
with ambulatory controls. Despite the lack of effect on bone
mass and architecture, IG9402 administration partially pre-
vented the decrease in ultimate load and ultimate stress in tail-
suspended mice.
Discussion
Accumulation of apoptotic osteocytes precedes osteoclast-
mediated resorption and the loss of bone induced by reduced
mechanical forces, and RANKL expression is increased with
unloading in mice (10, 14). Osteocytes are major producers of
RANKL (3). However, the role of these cells in pathological
bone resorption is unknown.Herewe tested the hypothesis that
apoptotic osteocytes signal to neighboring osteocytes to
increase RANKL expression, which, in turn, increases oste-
oclast formation and bone resorption in disuse osteoporosis.
Using the murine model of unloading by tail suspension, we
found that, indeed, prevention of osteocyte apoptosis blocks
the increase in RANKL expression in osteocytes. However,
inhibition of apoptosis and reduction of osteocytic RANKLwas
not sufficient to prevent the increase in osteoclasts or bone
resorption or the decrease in bone mass induced by unloading.
These findings are consistent with previous studies showing
that inhibition of apoptosis induced by fatigue loading results in
decreased RANKL expression in osteocytes (32) and add addi-
tional support to the notion that there is a cause-effect relation-
ship between osteocyte apoptosis and osteocytic RANKL. In
contrast to osteocyte apoptosis induced by fatigue loading,
however, the results of this study show that maintaining osteo-
cyte viability is not sufficient to restrain resorption or prevent
the loss of bone induced by unloading. These findings suggest
that RANKL derived from cells other than osteocytes is critical
for the increased osteoclastogenesis and the bone loss resulting
from reduced mechanical forces. Because RANKL expression
in osteoblasts is still high even when apoptosis is inhibited, our
data suggest that osteoblasts contribute to the enhanced
resorption in unloaded mice. Furthermore, on the basis of the
lack of effect of bisphosphonates onRANKLexpression in vitro,
either directly or through soluble factors released to the media,
we conclude that interactions between apoptotic osteocytes
and other cells of the bone/bone marrow microenvironment
that cannot be reproduced in vitro might be involved in the
regulation of RANKL downstream of osteocyte apoptosis. In
this regard, several molecules have been proposed asmediators
for the regulation of RANKL expression in osteocytes following
apoptosis, including VEGF and HMGB1 (3, 33). However, the
identity of the molecules that mediate the increase in resorp-
tion in unloaded mice is not known. Future studies are war-
ranted to investigate the cellular and molecular mechanism
underlying this phenomenon.
As shown in previous studies (14), unloading increased the
prevalence of apoptosis of osteocytes and osteoblasts. We
found that BPs (a traditional compound as well as a novel ana-
log that does not affect osteoclasts directly) prevented apopto-
sis of both osteocytes and osteoblasts. In addition, both BPs
prevented the increase in RANKL expression in osteocytes,
demonstrating that elevated expression of this cytokine is a
consequence of apoptosis in these cells. However, neither agent
prevented the increase in RANKL expression induced by
unloading in osteoblasts, demonstrating that unloading regu-
lates RANKL expression by differentmechanisms in osteocytes
versus osteoblasts. The decrease in OPG induced by unloading
in osteocytes was not reversed by the BPs, demonstrating that
this gene is not regulated by apoptosis. Similarly, IG9402 did
not reverse the decrease inOPG induced by unloading in osteo-
blasts. The increase in osteoblastic OPG observed in alendro-
nate-treated animals suggests that, besides its direct action on
osteoclasts, part of the antiresorptive effects of this BP might
result from effects on osteoblasts leading to up-regulation of
this antiosteoclastogenic cytokine. Indeed, increased OPG lev-
FIGURE 4. Abnormal osteoclasts accumulate in cancellous bone of alen-
dronate-treated mice. Representative images of vertebral cancellous bone
stained for TRAP show the presence of a giant osteoclast (white arrows) in the
ambulatory control mice and potential osteoclast remnants (black arrow) in
the tail-suspended mice receiving alendronate. Scale bars 25 m.
FIGURE 5. Alendronate, but not IG9402, prevented bone loss induced by
immobilization. Shown is the percent change of BMDmeasured in the total
body, spine, and femur. Error bars represent themean S.D. of 8–13 replicas.
*, p 0.05 versus the respective ambulatory control; #, p 0.05 versus saline-
treated, tail-suspended mice; two-way ANOVA.
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els induced by BPs have been shown previously in patients (34–
36) and in bone marrow/mesenchymal stem cells (37–39).
An association between osteocyte apoptosis and osteocytic
RANKL has also been reported for fatigue loading (32). In con-
trast to our study, in which inhibition of apoptosis with BPs did
not prevent the increase in bone resorption nor the loss of bone
mass, blocking osteocyte apoptosis induced by fatigue loading
with the pan caspase inhibitor quinolyl-valyl-O-methylaspar-
tyl-[2,6-difluorophenoxy]-methyl ketone (Q-VD-OPh) com-
pletely inhibited intracortical remodeling (40). The same
caspase inhibitor also prevented endocortical remodeling
induced by ovariectomy (41). In these latter cases, however,
resorption was evaluated only at the local level in cortical bone,
and systemic effects on circulating CTX or bonemass through-
out the skeleton were not reported.
Our work showing that restraining the increase in osteocytic
RANKL does not prevent the loss of bone with unloading con-
trasts with earlier studies demonstrating that mice lacking
RANKL in osteocytes are protected from bone loss induced by
unloading (10). A potential source for this difference is that the
increase in osteoclasts and the decrease in cancellous bone vol-
ume induced by tail suspension in the study by O’Brien and
FIGURE 6. IG9402 did not prevent the loss of bone volume and the changes in cancellous bone architecture induced by tail suspension. MicroCT
analysis showingpercent cancellous BV/TV and trabecular number (TbN), thickness (TbTh), and separation (TbSp) (A); cortical thickness (B), and total (cancellous
	 cortical) BV/TV in lumbar vertebrae (C). Error bars representmean S.D. of three to seven replicas. *,p 0.05 versus the respective ambulatory control; #,p
0.05 versus saline-treated, tail-suspended mice; two-way ANOVA. Representative microCT images of the cancellous vertebral bone are shown.
FIGURE 7. Alendronate and IG9402 prevented the decrease in bone
strength induced by tail suspension. Shown are the ultimate load and ulti-
mate stress of the vertebrae as determinedby compression testing. Error bars
represent mean  S.D. of 10–13 replicas. *, p  0.05 versus the respective
ambulatory control; #, p  0.05 versus saline-treated, tail-suspended mice;
two-way ANOVA.
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colleagues (10) were much smaller compared with our study,
likely because of the fact that they usedmice from both genders
and of mixed background. Another potential explanation is
that, in their study, RANKL was completely removed from
osteocytes instead of just preventing the increase in osteocytic
RANKL induced by tail suspension, as in our study. It is then
possible that a basal tonic expression of RANKL in osteocytes is
required for the bone loss induced by tail suspension by acting
in concert with RANKL expressed by other cells. In addition,
the DMP1–10kb-Cre mice used to delete the RANKL gene in
the study by O’Brien and colleagues (10) is also expressed in a
population of mature osteoblasts. Therefore, RANKL could
have been deleted from both osteocytes and some osteoblasts,
which, as we show in this study, exhibit increased RANKL
expression in unloaded mice. Then, the absence of RANKL
from both cell types is what is needed to halt osteoclastogenesis
and the loss of bone mass induced by unloading.
Even when IG9402 was not able to block the bone loss
induced by unloading, mice receiving this BP analog exhibited
more bone strength than vehicle-treated mice. Indeed, the
decrease in ultimate load by 46%, and, in maximum stress, by
62% induced by tail suspension in vehicle-treated mice was
reduced to a 38% decrease for both parameters in unloaded
mice treated with IG9402. Taken together with the survival
effect of IG9402 on osteoblasts and osteocytes, this evidence
suggests that preservation of osteocyte and osteoblast viability
by IG9402 contributes to maintain bone strength independent
of changes in bone mass.
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